

CLAIMS

1. A nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ϵ_{ijk} equal to or above 200, and an insulator material with a dielectric constant ϵ_{ijk} equal to or below 100.
2. The nanoparticle or nanoparticles' aggregate for use according to claim 1, wherein the electric field is applied through deep brain stimulation, transcranial electric stimulation or transcranial magnetic stimulation.
3. The nanoparticle or nanoparticles' aggregate for use according to claim 1 or 2, wherein the nanoparticle's or nanoparticles' aggregate's material is a conductor material selected from a metal having a standard reduction potential E° above 0.2 and an organic material having contiguous sp² hybridized carbon centers in its structure.
4. The nanoparticle or nanoparticles' aggregate for use according to claim 3, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a metallic nanoparticle wherein the metallic element is Ir, Pd, Pt, Au, or a mixture thereof, and an organic nanoparticle consisting of polyaniline, polypyrrole, polyacetylene, polythiophene, polycarbazole and/or polypyrene.
5. The nanoparticle or nanoparticles' aggregate for use according to claim 1 or 2, wherein the nanoparticle's or nanoparticles' aggregate's material is a semiconductor material with a band gap E_g below 3.0 eV.
6. The nanoparticle or nanoparticles' aggregate for use according to claim 5, wherein the nanoparticle's or nanoparticles' aggregate's material consists of an element from group IVA of the Mendeleev's periodic table, or in a mixed composition of elements from group III and V of the Mendeleev's periodic table, or in a mixed composition of elements from group II and VI of the Mendeleev's periodic table.
7. The nanoparticle or nanoparticles' aggregate for use according to claim 6, wherein the nanoparticle's or nanoparticles' aggregate's material consists of an element from group IVA

of the Mendeleev's periodic table and is doped with a charge carrier selected from Al, B, Ga, In and P.

- 5 8. The nanoparticle or nanoparticles' aggregate for use according to claim 1 or 2, wherein the material is an insulator material with a band gap E_g equal to or above 3.0 eV and the relative dielectric constant ϵ_{ijk} is measured between 20°C and 30°C and between 10^2 Hz up to the infrared frequency.
- 10 9. The nanoparticle or nanoparticles' aggregate for use according to claim 8, wherein the material is an insulator material with a band gap E_g equal to or above 3.0 eV and the relative dielectric constant ϵ_{ijk} is equal to or above 200 and the material of the nanoparticle or nanoparticles' aggregate is a dielectric material which is a mixed-metal oxide selected from BaTiO_3 , KTaNbO_3 , KTaO_3 , SrTiO_3 and BaSrTiO_3 .
- 15 10. The nanoparticle or nanoparticles' aggregate for use according to claim 8, wherein the material is an insulator material with a band gap E_g equal to or above 3.0 eV and the relative dielectric constant ϵ_{ijk} is equal to or below 100 and the material of the nanoparticle or nanoparticles' aggregate is a dielectric material which is selected from a metal oxide, a mixed metal oxide, the metallic element of which is from period 3, 5 or 6 of the Mendeleev's periodic table or a lanthanide, and a carbon material.
- 20 11. The nanoparticle for use according to anyone of claims 1 to 10, wherein the neurological disease is selected from Parkinson's disease, Alzheimer's disease, epilepsy, obsessive compulsive disorder, autism spectrum disorder, depression disorder, dystonia, Tourette's syndrome, schizophrenia, stroke, aphasia, dementia, tinnitus, Huntington's disease, essential tremor, bipolar disorder, anxiety disorder, addiction disorder, consciousness vegetative state, and at least one symptom thereof.
- 25 12. A composition for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject exposed to an electric field, wherein the composition comprises nanoparticles and/or nanoparticles' aggregates and a pharmaceutically acceptable support, and wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ϵ_{ijk} equal to or above 200, and an insulator material with a dielectric constant ϵ_{ijk} equal to or below 100.
- 30
- 35

13. The composition for use of claim 12, wherein the composition comprises at least two distinct nanoparticles and/or nanoparticles' aggregates, each nanoparticle or nanoparticles' aggregate consisting of a distinct material selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ϵ_{ijk} equal to or above 200 and an insulator material with a dielectric constant ϵ_{ijk} equal to or below 100.
14. A kit comprising at least two distinct nanoparticles and/or nanoparticles' aggregates, each nanoparticle or nanoparticles' aggregate consisting of a distinct material selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ϵ_{ijk} equal to or above 200 and an insulator material with a dielectric constant ϵ_{ijk} equal to or below 100.
15. The kit according to claim 14 for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject.